DB:NK8

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

NuVasive, Inc., a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery.


Snowflake Analysis

Solid track record and good value.


Similar Companies

Share Price & News

How has NuVasive's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NK8's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

NK8

-3.6%

DE Medical Equipment

6.8%

DE Market


1 Year Return

4.4%

NK8

31.3%

DE Medical Equipment

5.6%

DE Market

Return vs Industry: NK8 underperformed the German Medical Equipment industry which returned 33.7% over the past year.

Return vs Market: NK8 matched the German Market which returned 4.4% over the past year.


Shareholder returns

NK8IndustryMarket
7 Day0%-3.6%6.8%
30 Day1.9%4.3%14.0%
90 Day4.8%20.8%7.5%
1 Year4.4%4.4%32.9%31.3%7.4%5.6%
3 Year-23.8%-23.8%111.8%108.0%0.3%-7.3%
5 Year24.9%24.9%264.5%251.5%12.4%-2.0%

Price Volatility Vs. Market

How volatile is NuVasive's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is NuVasive undervalued compared to its fair value and its price relative to the market?

20.2%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: NK8 (€55) is trading below our estimate of fair value (€68.94)

Significantly Below Fair Value: NK8 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: NK8 is poor value based on its PE Ratio (52.2x) compared to the Medical Equipment industry average (49.6x).

PE vs Market: NK8 is poor value based on its PE Ratio (52.2x) compared to the German market (20.1x).


Price to Earnings Growth Ratio

PEG Ratio: NK8 is good value based on its PEG Ratio (0.9x)


Price to Book Ratio

PB vs Industry: NK8 is good value based on its PB Ratio (4x) compared to the DE Medical Equipment industry average (5.1x).


Next Steps

Future Growth

How is NuVasive forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?

61.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NK8's forecast earnings growth (61.2% per year) is above the savings rate (0.2%).

Earnings vs Market: NK8's earnings (61.2% per year) are forecast to grow faster than the German market (22.5% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: NK8's revenue (10.5% per year) is forecast to grow faster than the German market (5.7% per year).

High Growth Revenue: NK8's revenue (10.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: NK8's Return on Equity is forecast to be low in 3 years time (13.5%).


Next Steps

Past Performance

How has NuVasive performed over the past 5 years?

1.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NK8 has high quality earnings.

Growing Profit Margin: NK8's current net profit margins (5.3%) are higher than last year (4.4%).


Past Earnings Growth Analysis

Earnings Trend: NK8's earnings have grown by 1.1% per year over the past 5 years.

Accelerating Growth: NK8's earnings growth over the past year (24.7%) exceeds its 5-year average (1.1% per year).

Earnings vs Industry: NK8 earnings growth over the past year (24.7%) exceeded the Medical Equipment industry 8.2%.


Return on Equity

High ROE: NK8's Return on Equity (6.9%) is considered low.


Next Steps

Financial Health

How is NuVasive's financial position?


Financial Position Analysis

Short Term Liabilities: NK8's short term assets ($1.1B) exceed its short term liabilities ($782.1M).

Long Term Liabilities: NK8's short term assets ($1.1B) exceed its long term liabilities ($552.2M).


Debt to Equity History and Analysis

Debt Level: NK8's debt to equity ratio (111.7%) is considered high.

Reducing Debt: NK8's debt to equity ratio has increased from 54.9% to 111.7% over the past 5 years.

Debt Coverage: NK8's debt is well covered by operating cash flow (21.8%).

Interest Coverage: NK8's interest payments on its debt are well covered by EBIT (3.2x coverage).


Balance Sheet


Next Steps

Dividend

What is NuVasive's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NK8's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NK8's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NK8's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NK8's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NK8's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.4yrs

Average management tenure


CEO

Chris Barry (46yo)

1.58yrs

Tenure

US$5,425,435

Compensation

Mr. J. Christopher Barry serves as CEO and Director of NuVasive, Inc. since November 5, 218. Mr. Barry served commercial and leadership roles at Covidien. He has extensive experience as an innovative globa ...


CEO Compensation Analysis

Compensation vs Market: Chris's total compensation ($USD5.43M) is above average for companies of similar size in the German market ($USD2.40M).

Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
J. Barry
CEO & Director1.58yrsUS$5.43m0.019% $535.2k
Matthew Link
President1.42yrsUS$2.27m0.17% $4.6m
Nathaniel Sisitsky
Senior VP2.42yrsUS$1.14m0.020% $561.0k
Matthew Harbaugh
Executive VP & CFO0.42yrno datano data
Dale Wolf
Senior Vice President of Global Operations0.50yrno datano data
Johnson Lai
Chief Information Officer4.83yrsno datano data
Suzanne Hatcher
Vice President of Internal & External Affairsno datano datano data
Sean Freeman
Senior Vice President of Strategy & Corporate Development0.50yrno datano data
Lucas Vitale
Chief Human Resources Officer1.42yrsno data0.013% $371.5k
Frank Middeke
Managing Director of DACH6.5yrsno datano data

1.4yrs

Average Tenure

44.5yo

Average Age

Experienced Management: NK8's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
J. Barry
CEO & Director1.58yrsUS$5.43m0.019% $535.2k
John DeFord
Independent Director2.33yrsUS$230.06kno data
Robert Friel
Independent Director4.33yrsUS$230.06kno data
Vickie Capps
Independent Director5yrsUS$250.06kno data
Gregory Lucier
Chairman of the Board5.25yrsUS$830.06k0.43% $12.0m
R. Huennekens
Independent Director1.67yrsUS$230.06k0.0027% $73.6k
Daniel Wolterman
Independent Director4.92yrsUS$250.06kno data
Donald Rosenberg
Independent Lead Director2.08yrsUS$255.06k0.018% $498.5k
Leslie Norwalk
Independent Director6.08yrsUS$240.06kno data

4.3yrs

Average Tenure

57yo

Average Age

Experienced Board: NK8's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

NuVasive, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: NuVasive, Inc.
  • Ticker: NK8
  • Exchange: DB
  • Founded: 1997
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$3.148b
  • Listing Market Cap: US$2.779b
  • Shares outstanding: 51.25m
  • Website: https://www.nuvasive.com

Number of Employees


Location

  • NuVasive, Inc.
  • 7475 Lusk Boulevard
  • San Diego
  • California
  • 92121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NUVANasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMay 2004
NK8DB (Deutsche Boerse AG)YesCommon StockDEEURMay 2004
NUVA *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNMay 2004

Biography

NuVasive, Inc., a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company’s principal products include Maximum Access Surgery, a minimally disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprises products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons to access the spine to perform restorative and fusion procedures in a minimally disruptive fashion. The company’s biologics products include Osteocel Plus and Pro, a cellular bone matrix; Formagraft, a collagen-based synthetic bone substitute; AttraX, a synthetic bone graft material; and Propel DBM, a moldable demineralized bone matrix putty and gel. Its IOM services are used for onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company also provides implants used for interbody disc height restoration; and fixation products, including pedicle screws, rods, and plates. In addition, it offers Integrated Global Alignment platform for assessing, preserving, and restoring spinal alignment; MAGEC-early onset scoliosis, a spinal bracing and distraction system; and Precice, a limb lengthening system. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly-employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was founded in 1997 and is headquartered in San Diego, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/05 09:27
End of Day Share Price2020/06/04 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.